派西拉生物科学

最新新闻

• Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Pacira Pharmaceuticals (PCRX) and Beta Bionics, Inc. (BBNX)
  TipRanks · 2026/1/9
• 评级变动
  Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/5/1
• 评级变动
  Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Announces Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Truist Financial Initiates Pacira BioSciences(PCRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 评级变动
  Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $32
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Pacira Pharmaceuticals (PCRX) Receives a Sell From J.P. Morgan
  TipRanks · 2026/8/10
• 评级变动
  Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• 评级变动
  Analysts' Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)
  TipRanks · 2026/5/1
• Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• Leerink Partners Initiates Pacira BioSciences(PCRX.US) With Hold Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Cuts Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/3/26
• 评级变动
  Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• 评级变动
  H.C. Wainwright Reaffirms Their Buy Rating on Pacira Pharmaceuticals (PCRX)
  TipRanks · 2026/4/20
• 评级变动
  Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• 评级变动
  J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Sell Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/8/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。